Fig. 3
From: Neuroprotective effects of psilocybin in a rat model of stroke
Pretreatment with psilocybin reduced behavioral deficits in stroke rats. ANA12 antagonized psilocybin-mediated behavioral improvement. (A) Timeline. Psilocybin (Psi) was given (i.c.v.) 15 min before the MCAo on D0. ANA12 was delivered intranasally after the MCAo on days 0 and 1. Behavioral tests were conducted on D2. Cerebal ischemia significantly (#p<0.001) increased (B1) Bederson’s neurological score (F3,21=16.411) and (B2) body asymmetry (F3,21=23.904), while reduced locomotor activity (C1, HACTV, F3,21=39.745; C2, TOTDIST, F3,21=20.506; C3, MOVNO, F3,21=23.904; C4, MOVETIME, F3,21=10.713). These behavior responses were significantly antagonized (*p<0.05) by Psi (B1, Bederson’s score, F3,21=16.411; B2, body asymmetry, F3,21=23.904; C1, HACTV, F3,21=39.745; C2,TOTDIST, F3,21=20.506; C3, MOVNO, F3,21=23.904; C4, MOVETIME, F3,21=10.713). ANA12 significantly (*p<0.05) antagonized Psi-mediated behavioral improvement (B1, B2, C1, C2). [one-way ANOVA+NK test; HACTV: horizontal activity; TOTDIST: total distance traveled; MOVNO: movement number; MOVETIME: movement time]